Prosecution Insights
Prosecution Insights
Listed by the USPTO as GODDARD, LAURA B
Tech Center 1600 • Art Units: 1618 1642 1645 1646 1651 1671
This examiner grants 51% of resolved cases
Laura B Goddard has a volume of 1282 resolved cases in Art Unit 1618. Her allowance rate is 50.9%, and the median days to allowance is 1181. These figures indicate a prosecution environment where cases result in an allowance in Tech Center 1600. The number of resolved cases suggests an experienced examiner with this performance profile. Practitioners can rely on these metrics for strategic planning and setting expectations for the duration of their cases.
The interview lift of 13.5% suggests that interviews are beneficial and can improve the probability of an allowance compared to the baseline rate. This lift indicates that direct dialogue is a tool for resolving issues in her cases. Board of Regents of the University of Texas System, Genentech Inc., and Meso Scale Technologies LLC are her top companies, showing a focus on biotechnology and research. GOODWIN PROCTER LLP, Fox Rothschild LLP, and NORTON ROSE FULBRIGHT US LLP are the top firms.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17877195 | COMBINATION THERAPY WITH NEOANTIGEN VACCINE | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18048986 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | Final Rejection | Genentech, Inc. |
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | Non-Final OA | GENENTECH, INC. |
| 18409276 | METHODS AND COMPOSITIONS FOR ACTIVATION OF T CELLS USING NANOPARTICLES CONJUGATED WITH MULTIPLE LIGANDS FOR BINDING RECEPTORS ON T CELLS | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18035160 | HLA CLASS II-RESTRICTED TCRS AGAINST THE KRAS G12>V ACTIVATING MUTATION | Non-Final OA | The Regents of the University of California |
| 18389951 | ANTI-PD-1×4-1BB BINDING PROTEINS | Non-Final OA | Genzyme Corporation |
| 18478808 | CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18059719 | Treatment Of Lung Disease Based Upon Stratification Of Polygenic Score Relating To Response To A Therapeutic Agent | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18579142 | T Cell Receptors (TCR) to Human Papillomavirus Proteins, Compositions, and Uses Thereof | Non-Final OA | Emory University |
| 18022593 | Modulatory Substance of Tumor Immune Microenvironment, and Preventive, Diagnostic and/or Therapeutic Utilization of the Same | Final Rejection | The University Of Tokyo |
| 17786917 | METHODS FOR TREATING GLIOBLASTOMA | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17193511 | TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18561044 | POLY-ADP RIBOSE (PAR) TRACKER OPTIMIZED SPLIT-PROTEIN REASSEMBLY PAR DETECTION REAGENTS | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18438746 | METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR | Non-Final OA | Sanofi Biotechnology |
| 18553042 | VACCINE COMPOSITION AGAINST CORONAVIRUS | Final Rejection | LG CHEM, LTD. |
| 17535492 | METHODS OF TREATING UROTHELIAL CARCINOMA | Final Rejection | Foundation Medicine, Inc. |
| 18052840 | COMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19 | Final Rejection | AstraZeneca UK Limited |
| 18335235 | RNF167 AND CASTOR1 AS NOVEL MTOR TARGETS | Final Rejection | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18496065 | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS FOR CANCER | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 17667714 | BIOMARKERS OF THERAPEUTIC RESPONSIVENESS | Final Rejection | Meso Scale Technologies, LLC. |
| 17394512 | BIOMARKERS OF THERAPEUTIC RESPONSIVENESS | Non-Final OA | Meso Scale Technologies, LLC. |
| 18504497 | REDUCING JUNCTION EPITOPE PRESENTATION FOR NEOANTIGENS | Non-Final OA | Gritstone bio, Inc. |
| 18595834 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Non-Final OA | Mersana Therapeutics, Inc. |
| 16646986 | CD19CART CELLS ELIMINATE MYELOMA CELLS THAT EXPRESS VERY LOW LEVELS OF CD19 | Final Rejection | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG |
| 18251832 | MEANS AND METHODS FOR TREATING SUBJECTS WITH ERBB3 MUTATION POSITIVE CANCER | Final Rejection | Merus N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.9% of resolved applications examined by Laura B Goddard were allowed (1,282 resolved cases), compared with 33.1% across Art Unit 1618 over the last five years.
This examiner's interview lift is +13.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Laura B Goddard took 1,181 days on average from filing to allowance.
Laura B Goddard examines applications in Art Unit 1618 in Tech Center 1600 (Biotechnology & Pharmaceuticals).